Bristol Myers Squibb (CELG-RI) Cash from Investing Activities (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has reported Cash from Investing Activities for 18 consecutive years, with -$1.6 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash from Investing Activities fell 241.23% year-over-year to -$1.6 billion; the TTM figure through Jun 2026 stood at -$4.9 billion (down 253.64% YoY), while the FY2025 annual figure was -$4.1 billion, up 80.65% from the prior year.
• Cash from Investing Activities retreated to -$1.6 billion in Q2 2026 per CELG-RI's latest filing, from -$131.0 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $1.2 billion in Q4 2022 and bottomed at -$19.6 billion in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$1.7 billion across 5 years, with a median of -$441.5 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Investing Activities surged 202.49% — and 2024, when it slumped 9241.9%.
• Bristol Myers Squibb's Cash from Investing Activities stood at $1.2 billion in 2022, then plunged by 210.96% to -$1.3 billion in 2023, then surged by 85.44% to -$196.0 million in 2024, then tumbled by 643.88% to -$1.5 billion in 2025, then retreated by 10.7% to -$1.6 billion in 2026.
• Business Quant data shows CELG-RI's Cash from Investing Activities at -$1.6 billion in Q2 2026, -$131.0 million in Q1 2026, and -$1.5 billion in Q4 2025.